Idorsia Ltd, a Swiss biotechnology company, has seen its stock price and market presence bolstered by recent developments, including the inclusion of its blood pressure medication in US guidelines and a positive outlook from Deutsche Bank.

Idorsia Ltd’s promising insomnia treatment, daridorexant, offers a glimmer of hope amidst the company’s financial struggles.